Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 12/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | MARK3 | P27448 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935719 | 0.79 | ADK (0.48) | ADKSLC29A1CHEK1SRCMEN1 | |
| SCHEMBL16236531 | 0.78 | ADK (0.44) | ADKSLC29A1CHEK1SRCMEN1 | |
| SCHEMBL12934032 | 0.78 | ADK (0.46) | ADKSLC29A1CHEK1SRCMEN1 | |
| SCHEMBL18658456 | 0.78 | ADK (0.34) | ADKSLC29A1ADORA2AADORA1DYRK3 | |
| SCHEMBL16790663 | 0.78 | ADK (0.46) | ADKSLC29A1CHEK1SRCMEN1 | |
| SCHEMBL868823 | 0.78 | ADK (0.49) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL1585102 | 0.78 | ADK (0.49) | ADKADORA2AADORA1DYRK3ROCK2 | |
| SCHEMBL20005608 | 0.78 | ADK (0.46) | ADKSLC29A1CHEK1SRCMEN1 | |
| SCHEMBL29589509 | 0.77 | ADK (0.46) | ADKSLC29A1CHEK1SRC | |
| SCHEMBL16236999 | 0.77 | ADK (0.46) | ADKSLC29A1CHEK1SRCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340557-A | Synthesis method of 4-chloro-5-iodo-7-methyl-7H-pyrrolo [2,3-d ] pyrimidine | 安徽大学 | 2022-11-15 | — | — | CN | claimed |
| WO-2025103465-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 上海齐鲁制药研究中心有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| CN-101506211-A | Kinase antagonists | UNIV CALIFORNIA (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-2004654-A2 | KINASE ANTAGONISTS | The Regents of the University of California (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007114926-A2 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | ADK 141/4885SLC29A1 1578/4885CHEK1 434/4885 |
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | ADK 267/4885SLC29A1 3387/4885CHEK1 352/4885 |
| US-20110301144-A1 | Kinase Antagonists | MTOR, RPS6KA3, AKT3 | ADK 267/4885SLC29A1 3387/4885CHEK1 352/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | ADK 961/4885SLC29A1 4812/4885CHEK1 290/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | ADK 961/4885SLC29A1 4812/4885CHEK1 290/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | ADK 157/4885SLC29A1 1093/4885CHEK1 469/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | ADK 208/4885SLC29A1 2182/4885CHEK1 520/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | ADK 231/4885SLC29A1 1311/4885CHEK1 169/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | ADK 249/4885SLC29A1 4263/4885CHEK1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.